MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Trevena Market Cap 2011-2026 | TRVN
As of April 27, 2026 Trevena has a market cap of $ 31.8 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Trevena
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.09 M | 5.09 M | 3.81 M | 278 M | 79.8 M | 82.4 M | 103 M | 343 M | 319 M | 134 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 343 M | 3.81 M | 135 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
315 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
1.25 B | $ 21.77 | 1.68 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
127 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
724 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
79 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
33.6 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
6.69 M | $ 0.92 | 3.05 % | $ 6.76 M | China |
 |
Biophytis SA
BPTS
|
549 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
168 B | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
3.19 B | $ 22.44 | 2.16 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
28.9 M | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
561 M | $ 2.02 | 5.76 % | $ 420 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
19.6 M | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
178 M | $ 2.42 | 3.65 % | $ 155 M | USA |
 |
Akouos
AKUS
|
172 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
13.1 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
2.83 B | - | - | - |  Russia |
 |
Heron Therapeutics
HRTX
|
198 M | $ 1.26 | 6.3 % | $ 210 M | USA |
 |
Applied Molecular Transport
AMTI
|
22.1 M | - | - | $ 10.1 M | USA |
 |
ImmuCell Corporation
ICCC
|
58 M | $ 8.28 | -0.84 % | $ 74.7 M | USA |
 |
Aeterna Zentaris
AEZS
|
41.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
6.33 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
541 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
9.48 M | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
14.1 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
60.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
InflaRx N.V.
IFRX
|
149 M | $ 1.53 | 3.38 % | $ 152 M | Germany |
 |
Aridis Pharmaceuticals
ARDS
|
4.13 M | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
62.9 B | $ 103.31 | -2.04 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
544 K | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
32.8 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
467 M | $ 4.14 | 1.47 % | $ 443 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
3.44 B | $ 23.57 | 1.33 % | $ 3 B | USA |
 |
Innate Pharma S.A.
IPHA
|
363 M | $ 1.39 | 0.72 % | $ 235 M | France |
 |
Inventiva S.A.
IVA
|
535 M | $ 5.18 | 0.49 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
956 K | $ 0.36 | -8.39 % | $ 840 K | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
322 M | $ 1.46 | 1.04 % | $ 389 M | Britain |
 |
Aptose Biosciences
APTO
|
2.32 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
81.2 B | - | - | $ 96.9 B | Britain |
 |
KalVista Pharmaceuticals
KALV
|
836 M | $ 20.08 | 2.29 % | $ 1.08 B | Britain |
 |
AVROBIO
AVRO
|
56.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 2.99 | 2.05 % | $ 4.92 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
308 M | - | -4.8 % | $ 255 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
132 M | $ 12.42 | 1.26 % | $ 1.65 B |  Australia |
 |
BeiGene, Ltd.
BGNE
|
253 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
3.25 B | - | - | $ 3.67 B | USA |